Devdatt (Dev) Kurdikar is the CEO of Embecta Corp., a company focused on diabetes management solutions. Born in 1978, Dev holds an MBA from a top business school, which laid the foundation for his career in management. He became CEO...

Devdatt (Dev) Kurdikar is the CEO of Embecta Corp., a company focused on diabetes management solutions. Born in 1978, Dev holds an MBA from a top business school, which laid the foundation for his career in management. He became CEO in April 2022, shortly after Embecta's separation from BD, where he had been with the diabetes care unit. Under his leadership, the company's focus is on driving performance-based strategies that align with long-term stockholder interests. In fiscal year 2023, Dev's total compensation was approximately $1.97 million, which included a significant performance-based bonus that reflects his impact on the company’s growth. Interesting to note, he received a one-time equity grant as part of the transition to Embecta, signaling a strong commitment to the company’s future. Dev’s leadership style emphasizes transparency and alignment between executive compensation and company performance, which reflects in the company’s pay-for-performance philosophy. Outside of his role, he has a stake in the company through equity awards, which keeps him vested in Embecta’s success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

E

Devdatt Kurdikar

CEO of Embecta Corp.

Education

Ph.D. in Chemical Engineering from Purdue University, MBA from Washington University in St. Louis.

Field of Expertise

Technology & Engineering - Engineering

Sector of Economy

Healthcare

Born

January 1, 1968 - 57 years ago

CEO of Embecta Corp. for

3 years 2 months (Apr 2022 - Present)

Previous Experience

Worldwide President of Diabetes Care at BD, President and CEO of Cardiac Science Corporation, Vice President and General Manager at Boston Scientific.

Rivals

Competitors/colleagues of Devdatt Kurdikar

Holdings

See how much did Devdatt Kurdikar make over time.

As of October 2023, Dev Kudhikar holds a notable amount of Embecta stock. His holdings saw significant changes since the company’s formation, marking his commitment to the company’s growth. Back in 2022, his wealth was tied up in BD's assets...

As of October 2023, Dev Kudhikar holds a notable amount of Embecta stock. His holdings saw significant changes since the company’s formation, marking his commitment to the company’s growth. Back in 2022, his wealth was tied up in BD's assets before transitioning after the company’s spin-off. The market value of his shares fluctuates, highlighting both the company's ups and downs in the competitive diabetes management market. Recently, his equity awards reached a market value of approximately $1.25 million, showing that he remains heavily invested in Embecta's long-term success. This financial stake emphasizes his alignment with the interests of shareholders, as his compensation depends on the company’s performance metrics. This ensures he works towards increasing shareholder value in a sustainable way.

Mar 11, 2025

E

shares

EMBC @ $14.16

Z

shares

ZBH @ $107.28

Insider Trading

See recent insider trades of Devdatt Kurdikar.

EMBC

187,166 shares

EMBC

Nov 26, 2024

Received

EMBC

178,674 shares

EMBC

Nov 26, 2023

Received

EMBC

$109.05K

EMBC at $21.81/share

Aug 10, 2023

Purchase

EMBC

83,233 shares

EMBC

Nov 26, 2022

Received

EMBC

91,171 shares

EMBC

Apr 4, 2022

Received

EMBC

98,903 shares

EMBC

Apr 1, 2022

Received

Compensation History

See how much did Devdatt Kurdikar make over time.

In the fiscal year 2023, Devdatt Kurdikar’s total compensation was around $1.97 million, including an annual salary of $863,462 and a substantial performance-based bonus of $1.26 million. This highlights his focus on performance-driven results as the CEO. Notably, no stock awards vested in 2023, which indicates that his compensation package is primarily linked to short-term performance metrics rather than guaranteed equity compensation. The bonus he earned was reflective of meeting specific financial goals set for the company, underlining the CEO's commitment to driving sustainable growth. His compensation strategy aligns with Embecta's aim to enhance shareholder value by directly linking executive rewards to business performance, driving a culture of accountability and results.

Year

2023

Total Compensation

$2.20M

Salary

$863.46K

Board Justification

Embecta's compensation philosophy is designed to align the interests of executive officers with those of stockholders by providing pay that is directly linked to the achievement of performance goals established to foster the creation of sustainable long-term stockholder value.

Bonus

$1.26M

Board Justification

The annual incentive award earned under the Bonus Plan for fiscal year 2023, based on performance against pre-established objectives.

Other

$69.75K

Board Justification

Includes employer contributions to 401(k) and DCP plans, and other compensation elements.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock awards vested in 2023, as the amounts reported in the Summary Compensation Table reflect the aggregate accounting value of stock awards granted, not those that vested.

Performance Metrics

Performance metrics for 2023 included financial metrics such as Constant Currency Revenue and Adjusted EBITDA, along with strategic objectives.